28/05/2026
97.6% of patients prescribed cannabis-based medicines for anxiety, depression or post-traumatic stress disorder reported an improvement in symptoms, according to a first-of-its-kind UK multi-clinic patient survey.
For patients living with complex, treatment-resistant conditions, symptom improvement can have a significant impact on daily life.
Sometimes, meaningful progress looks like:
✅ Feeling more stable day to day
✅ Sleeping more consistently
✅ Managing symptoms more effectively
✅ Participating more fully in work, relationships and everyday routines
What this data brings into focus:
🌿 Patient-reported outcomes deserve thoughtful clinical attention
🌿 Symptom improvement should be viewed alongside wider quality-of-life measures
🌿 Prescribed medical cannabis should be understood within a regulated, specialist-led framework
🌿 Emerging real-world evidence can help move the conversation beyond stigma
Survey data is not a substitute for randomised controlled trials, and prescribed medical cannabis is not suitable for every patient. However, when a large group of patients consistently report meaningful improvements in symptoms and quality of life, those experiences should not be dismissed.
At Mamedica, we believe the discussion around prescribed medical cannabis should be guided by evidence, patient experience and responsible clinical oversight.